The Cardioprotective Effects of Adding Ozone To Cardioplegic Solution in Adult Cardiac Surgery

Assiut University

Status and phase: Unknown; Phase 3; Phase 2

Conditions: Ischemic Heart Disease

Treatments: Drug: Cardioplegic Solutions; Drug: Ozone

Study type: Interventional

Funder types: Other

Identifiers

NCT03876067

AssuitUlotfallah

Details and patient eligibility

About

forty patients with age ranged between 40-70 years undergoing elective coronary artery bypass graft surgery with cardiopulmonary bypass will be included, they will divided into two groups.

Ozone Group: in which Ozone will be added to cold blood cardioplegia. Control Group: in which in which only cold blood cardioplegia

Primary outcome:

Pattern of recovery of myocardium after declamping of Aorta

1. Time of cardiac rhythm return after declamping.
2. type of cardiac rhythm after declamping and rate of DC use.

Secondary outcome:

A-cardiac parameters

• Post operative inotropic score
• Incidence of post operative cardiac dysrhythmias
• postoperative ejection fraction (EF)
• Postoperative parameters of myocardial ischaemia
• a- Troponin levels
• b-Pro BNP
• • Histopathology of myocardial sample for detection of myocyte cellular edema as a marker of ischemic changes.

B-non cardiac parameters:

1. inflammatory markers 1. CRP 2. L\N 3. P\N
2. ICU stay
3. hospital stay
4. morbidity and mortality

Full description

Ozone Administration Protocol

Our procedures for O3T application in CBP surgery conform to international guidelines of the ''Madrid Declaration on Ozone Therapy'' 32 . M-O3T will be carried out as follows:

50mL of blood drawn by vacuum from the patient central catheter into a sterile blood transfusion bag in which 10 mL of 3.8% Na citrate solution (Galenica Senese Industries, Siena, Italy) as an anticoagulant will be previously added so that the blood/citrate volume ratio was 9:1. After blood withdrawal, the bag will momentarily disconnected leaving the venous access open by a saline infusion 33 . A corresponding volume (50 mL) of gas was immediately added with an O3 concentration of 20-50 micrograms/mL gas. Ozone was produced by Medozon compact generator (Herrmann Apparatebau GmbH, Germany).

The gas is immediately and continuously mixed with the blood in the bag for at least 5 min and with gentle rotating movement to avoid foaming. Due to the blood viscosity, the gas mixture does not instantaneously come into contact with the whole blood mass, thus this mixing time is necessary. During these 5 min of mixing, the ozone totally reacted with both the potent antioxidants of plasma and the unsaturated lipids bound to albumin, generating asmall amount of hydrogen peroxide and alkenals. These two messengers were responsible for eliciting crucial biochemical reactions on both erythrocytes and within cells. At this point, the hyper-oxygenated ozonated blood will be mixed with the cold cardioplegia (Thomsons cardioplegia) this amount of ozonated blood will be added to each 500 ml of cardioplegic solution

Exclusion Criteria:

The patient will be excluded from the study if he has any of the following:

• left ventricular ejection fraction< 40%
• diabetic or other metabolic disorders,
• use of left ventricular assist devices,
• Renal failure or on hemodialysis
• Hepatic dysfunction
• Hypothyroidism
• implanted pacemaker

Enrollment: 40 estimated patients

Sex: All

Ages: 40 to 70 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• patients undergoing elective CABG surgery

Exclusion criteria

• • left ventricular ejection fraction< 40%

  • diabetic or other metabolic disorders,
  • use of left ventricular assist devices,
  • Renal failure or on hemodialysis
  • Hepatic dysfunction
  • Hypothyroidism
  • implanted pacemaker

Trial design

Primary purpose: Supportive Care

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

40 participants in 2 patient groups, including a placebo group

Ozone Group

Experimental group

Description:

in which Ozone will be added to cold blood cardioplegia

Treatment:

Drug: Ozone

Control Group

Placebo Comparator group

Description:

: in which in which only cold blood cardioplegia

Treatment:

Drug: Cardioplegic Solutions